{"title":"在Merz制药出价后，Valeant提高了对Obagi医疗产品的报价","authors":"Heather Cartwright","doi":"10.3833/PDR.V2013I4.1917","DOIUrl":null,"url":null,"abstract":"Valeant Pharmaceuticals International has made a sweetened offer to acquire Obagi Medical Products, a California-based developer of physician-dispensed skincare systems, for US$24 per share. The company revised its March 2013 offer of US$19.75 per share after Obagi received an unsolicited bid of US$22 per share from Germany’s Merz Pharma. The Board of Directors of Obagi has approved the revised offer, which values the company at approximately US$418 M. Valeant has built its dermatology franchise via M&A, most notably acquiring Medicis Pharmaceutical for US$2.6 B in December 2012.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"39 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2013-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Valeant Increases Offer for Obagi Medical Products After Merz Pharma Bid\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/PDR.V2013I4.1917\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Valeant Pharmaceuticals International has made a sweetened offer to acquire Obagi Medical Products, a California-based developer of physician-dispensed skincare systems, for US$24 per share. The company revised its March 2013 offer of US$19.75 per share after Obagi received an unsolicited bid of US$22 per share from Germany’s Merz Pharma. The Board of Directors of Obagi has approved the revised offer, which values the company at approximately US$418 M. Valeant has built its dermatology franchise via M&A, most notably acquiring Medicis Pharmaceutical for US$2.6 B in December 2012.\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"39 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2013-05-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/PDR.V2013I4.1917\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2013I4.1917","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Valeant Increases Offer for Obagi Medical Products After Merz Pharma Bid
Valeant Pharmaceuticals International has made a sweetened offer to acquire Obagi Medical Products, a California-based developer of physician-dispensed skincare systems, for US$24 per share. The company revised its March 2013 offer of US$19.75 per share after Obagi received an unsolicited bid of US$22 per share from Germany’s Merz Pharma. The Board of Directors of Obagi has approved the revised offer, which values the company at approximately US$418 M. Valeant has built its dermatology franchise via M&A, most notably acquiring Medicis Pharmaceutical for US$2.6 B in December 2012.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
